AKT1 and renal carcinoma: However, in light of the suggestion that inhibition of FOXO might underlie the poor outcomes in renal cancer with vistusertib27, we assessed PI3K/AKT pathway signalling at baseline and at 1 and 24 h post-treatment with 2 μM vistusertib (Fig. 6).